JP2018039827A - Oral liquid composition - Google Patents
Oral liquid composition Download PDFInfo
- Publication number
- JP2018039827A JP2018039827A JP2017202409A JP2017202409A JP2018039827A JP 2018039827 A JP2018039827 A JP 2018039827A JP 2017202409 A JP2017202409 A JP 2017202409A JP 2017202409 A JP2017202409 A JP 2017202409A JP 2018039827 A JP2018039827 A JP 2018039827A
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- polyoxyethylene
- examples
- component
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 239000007788 liquid Substances 0.000 title claims abstract description 43
- -1 polyoxyethylene lauryl ether Polymers 0.000 claims abstract description 50
- 229940088594 vitamin Drugs 0.000 claims abstract description 21
- 229930003231 vitamin Natural products 0.000 claims abstract description 21
- 235000013343 vitamin Nutrition 0.000 claims abstract description 21
- 239000011782 vitamin Substances 0.000 claims abstract description 21
- 239000012676 herbal extract Substances 0.000 claims abstract description 14
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 41
- 235000011187 glycerol Nutrition 0.000 claims description 20
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 10
- 150000005846 sugar alcohols Polymers 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 4
- 238000013329 compounding Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 238000001556 precipitation Methods 0.000 abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 48
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 32
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 16
- 235000015165 citric acid Nutrition 0.000 description 16
- 229940042585 tocopherol acetate Drugs 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 239000011521 glass Substances 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 230000007774 longterm Effects 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 229930003448 Vitamin K Natural products 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 235000019168 vitamin K Nutrition 0.000 description 4
- 239000011712 vitamin K Substances 0.000 description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- 229940046010 vitamin k Drugs 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940008396 carrot extract Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229940116257 pepper extract Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000003237 Hedychium spicatum Species 0.000 description 1
- 235000015030 Hedychium spicatum Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000340987 Ptychopetalum olacoides Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001109 policosanol Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、難水溶性ビタミン、油成分、又は生薬抽出物を液体組成物中に長期間安定に溶解した内服液体組成物に関する。 The present invention relates to an internal liquid composition in which a poorly water-soluble vitamin, an oil component, or a herbal extract is stably dissolved in a liquid composition for a long period of time.
難水溶性ビタミン、油成分などの難水溶性成分や、生薬抽出物を低ｐＨ下でドリンク剤等の飲料に配合する場合、可溶化剤が必要となる。難水溶性成分に可溶化剤が必要なのは当然であるが、生薬抽出物においても、加水分解により長期的に濁りや沈殿を生じるため、可溶化剤が必要である。なお、ドリンク剤等の飲料は防腐性や風味等の観点から低ｐＨが適している。 When a poorly water-soluble component such as a poorly water-soluble vitamin or oil component or a herbal extract is blended in a beverage such as a drink at a low pH, a solubilizer is required. Naturally, a solubilizer is required for the poorly water-soluble component, but also in a crude drug extract, a solubilizer is necessary because it causes turbidity and precipitation in the long term due to hydrolysis. In addition, low pH is suitable for drinks, such as a drink agent, from viewpoints, such as antiseptic | preservation property and flavor.
しかしながら、食品や医薬品等に配合される経口可能な可溶化剤の多くは、低ｐＨ領域では長期保存時に可溶化剤由来の濁りや沈殿を生じてしまうことが課題とされていた（特許文献１）。 However, many of the orally-soluble solubilizers blended in foods and pharmaceuticals have been subject to turbidity and precipitation derived from the solubilizer during long-term storage in a low pH region (Patent Document 1). ).
したがって本発明は、低ｐＨでも、濁り・沈殿を生じさせることなく、難水溶性ビタミン、油成分、又は生薬抽出物を長期間安定に溶解させた内服液体組成物を提供することを課題とする。 Accordingly, an object of the present invention is to provide an internal liquid composition in which a poorly water-soluble vitamin, oil component, or herbal extract is stably dissolved for a long period of time without causing turbidity or precipitation even at a low pH. .
本発明者らは、かかる課題を解決すべく鋭意検討を重ねた結果、可溶化剤としてポリオキシエチレンラウリルエーテル、ポリオキシエチレンフィトステロール、及びポリオキシエチレンフィトスタノールから選ばれる１種以上を用い、さらに多価アルコール類を配合することで、難水溶性ビタミン、油成分、又は生薬抽出物を長期間安定に溶解させることができることを見出した。 As a result of intensive studies to solve such problems, the present inventors used one or more selected from polyoxyethylene lauryl ether, polyoxyethylene phytosterol, and polyoxyethylene phytostanol as a solubilizer, It has been found that a poorly water-soluble vitamin, an oil component, or a herbal extract can be stably dissolved for a long period of time by blending polyhydric alcohols.
かかる知見に基づき完成した本発明の態様は、
（１）ａ）難水溶性ビタミン、油成分、及び生薬抽出物から選ばれる１種以上、ｂ）ポリオキシエチレンラウリルエーテル、ポリオキシエチレンフィトステロール、及びポリオキシエチレンフィトスタノールから選ばれる１種以上、及びｃ）多価アルコール類、を含有することを特徴とする内服液体組成物、
（２）ｐＨが２．０〜４．０である（１）に記載の内服液体組成物、
（３）多価アルコール類としてグリセリン、及びソルビトールから選ばれる１種以上を含有する（１）又は（２）に記載の内服液体組成物、
（４）ｂ）及びｃ）成分の配合量が、ａ）成分の配合量１質量部に対して０．０２〜５００質量部である（１）〜（３）のいずれか１項に記載の内服液体組成物、
である。
The aspect of the present invention completed based on such findings is as follows.
(1) a) one or more selected from poorly water-soluble vitamins, oil components, and herbal extracts, b) one or more selected from polyoxyethylene lauryl ether, polyoxyethylene phytosterol, and polyoxyethylene phytostanol, And c) a polyhydric alcohol, an internal liquid composition,
(2) The internal liquid composition according to (1), wherein the pH is 2.0 to 4.0,
(3) The internal liquid composition according to (1) or (2), which contains at least one selected from glycerin and sorbitol as polyhydric alcohols,
(4) The blending amount of the components b) and c) is 0.02 to 500 parts by mass with respect to 1 part by mass of the component a). (1) to (3) Oral liquid composition,
It is.
本発明により、難水溶性ビタミン、油成分、又は生薬抽出物を長期間安定に溶解させる透明な内服液体組成物を得ることができる。 According to the present invention, it is possible to obtain a transparent liquid composition for internal use in which a poorly water-soluble vitamin, oil component, or herbal extract is stably dissolved for a long period of time.
本発明で用いる難水溶性ビタミンとは、内服可能な難水溶性ビタミンをいい、例えばビタミンＥ、ビタミンＥ脂肪酸エステル等のビタミンＥ誘導体（例えば、酢酸トコフェロール）、ビタミンＡ、ビタミンＤ、ビタミンＫが挙げられる。油成分とは生理活性を有する脂溶性物質や香料（合成香料・天然香料）、精油類であって内服可能なものをいい、生理活性を有する脂溶性物質とは例えばγ−オリザノール、γ−リノレン酸、ルテイン、ポリコサノール、ＣｏＱ１０、セラミド、レスベラトロール、アスタキサンチン、アマニ油、ＥＰＡ、トウガラシ抽出物や胡椒抽出物等であり、香料（合成香料・天然香料）、精油類とは例えばシトラール、リモネン等の合成或いは天然由来の香料または精油類が挙げられる。難水溶性ビタミン、油成分は単独で配合してもよく、２種以上を組み合わせて配合してもよい。内服液体組成物中へのこれらの配合量は特に限定されないが、好ましくは０．０００１乃至１質量％、より好ましくは０．００１乃至０．５質量％、もっとも好ましくは０．００２乃至０．０５質量％である。 The sparingly water-soluble vitamin used in the present invention refers to a sparingly water-soluble vitamin that can be taken internally, such as vitamin E, vitamin E derivatives such as vitamin E fatty acid esters (for example, tocopherol acetate), vitamin A, vitamin D, and vitamin K. Can be mentioned. The oil component means a fat-soluble substance having a biological activity, a fragrance (synthetic fragrance / natural fragrance), or an essential oil that can be used internally. Examples of the fat-soluble substance having a physiological activity include γ-oryzanol and γ-linolene. Acid, lutein, policosanol, CoQ10, ceramide, resveratrol, astaxanthin, linseed oil, EPA, pepper extract, pepper extract, etc. Examples of fragrances (synthetic fragrances / natural fragrances) and essential oils include citral, limonene, etc. Or natural-derived fragrances or essential oils. The poorly water-soluble vitamin and oil component may be blended alone or in combination of two or more. The blending amount of these in the internal liquid composition is not particularly limited, but is preferably 0.0001 to 1% by mass, more preferably 0.001 to 0.5% by mass, and most preferably 0.002 to 0.05%. % By mass.
本発明で用いる生薬抽出物はエキス末、抽出エキス、流エキスなどであるが、内服可能であれば特に限定されることはなく、生薬としてはニンジン、オウギ、オウセイ、カンゾウ、タイソウ、チンピ、ビャクジュツ、サンヤク、ブクリョウ、シュクシャ、ジオウ、トウキ、クコシ、カシュウ、リュウガンニク、シャクヤク、センキュウ、ニクジュヨウ、ジャショウシ、トシシ、トチュウ、ロクジョウ、イカリソウ、カイクジン、トウチュウカソウ、カイバ、オンジ、ヨクイニン、サンシュユ、ゴミシ、ショウキョウ、サイコ、ケイヒ、ハンピ、ムイラプアマ、バクモンドウ、ゴオウ、ジョテイシなどが挙げられる。これらは単独で配合してもよく、２種以上を組み合わせて配合してもよい。内服液体組成物中へのこれらの配合量は特に限定されないが、好ましくは０．０００１乃至１質量％、より好ましくは０．００１乃至０．５質量％、もっとも好ましくは０．００２乃至０．０５質量％である。 Herbal extracts used in the present invention are extract powder, extract extract, flow extract, etc., but are not particularly limited as long as they can be taken orally, and herbal medicines include carrots, rouges, scallions, licorice, taisou, chimpi, sandalwood. , Sanyaku, Bukuryo, Shukusha, Ziou, Touki, Kokushi, Kashu, Ryuganiku, Peonies, Senkyu, Nikujuyo, Jashoushi, Toshishi, Tochu, Rokujou, Ikarisou, Kaikujin, Tochuukaso, Kaiba, Onji, Yakuinin , Psycho, Keihi, Hampi, Muirapuama, Bakumondo, Gooh, and Joteishi. These may be blended singly or in combination of two or more. The blending amount of these in the internal liquid composition is not particularly limited, but is preferably 0.0001 to 1% by mass, more preferably 0.001 to 0.5% by mass, and most preferably 0.002 to 0.05%. % By mass.
本発明で用いるポリオキシエチレンラウリルエーテルはオキシエチレンの付加モル数が５〜５０モルであり、ポリオキシエチレンフィトステロール、ポリオキシエチレンフィトスタノールはオキシエチレンの付加モル数が５〜５０モルであるポリオキシエチレンフィトステロールである。具体的には、ポリオキシエチレン（２５モル）ラウリルエーテル、ポリオキシエチレン（５モル）フィトステロール、ポリオキシエチレン（１０モル）フィトステロール、ポリオキシエチレン（２０モル）フィトステロール、ポリオキシエチレン（３０モル）フィトステロール、ポリオキシエチレン（２５モル）フィトスタノール等が挙げられ、これらは単独で配合してもよく、２種以上を組み合わせて配合してもよい。 The polyoxyethylene lauryl ether used in the present invention has an addition mole number of oxyethylene of 5 to 50 moles, and the polyoxyethylene phytosterol and polyoxyethylene phytostanol have a polyoxyethylene addition mole number of 5 to 50 moles. Ethylene phytosterol. Specifically, polyoxyethylene (25 mol) lauryl ether, polyoxyethylene (5 mol) phytosterol, polyoxyethylene (10 mol) phytosterol, polyoxyethylene (20 mol) phytosterol, polyoxyethylene (30 mol) phytosterol , Polyoxyethylene (25 mol) phytostanol, and the like. These may be used alone or in combination of two or more.
ポリオキシエチレンラウリルエーテル、ポリオキシエチレンフィトステロール、及びポリオキシエチレンフィトスタノールから選ばれる１種以上の配合量は特に限定されないが、難水溶性ビタミン、油成分、及び生薬抽出物から選ばれる１種以上の１質量部に対して通常は０．０２〜５００質量部、好ましくは０．０５〜２００質量部、より好ましくは０．５〜１００質量部である。ポリオキシエチレンラウリルエーテル、ポリオキシエチレンフィトステロール、又はポリオキシエチレンフィトスタノールの配合量が少ないと濁りや沈殿を生成し、商品性が良くかつ安定な液体組成物を得ることができないことがある。 The amount of one or more selected from polyoxyethylene lauryl ether, polyoxyethylene phytosterol, and polyoxyethylene phytostanol is not particularly limited, but one or more selected from poorly water-soluble vitamins, oil components, and herbal extracts The amount is usually 0.02 to 500 parts by mass, preferably 0.05 to 200 parts by mass, and more preferably 0.5 to 100 parts by mass with respect to 1 part by mass. If the amount of polyoxyethylene lauryl ether, polyoxyethylene phytosterol, or polyoxyethylene phytostanol is too small, turbidity and precipitation may be generated, and a liquid composition with good commercial properties and stability may not be obtained.
本発明で用いる多価アルコール類としては、例えばエチレングリコール、プロピレングリコール、１、３−ブチレングリコール、ジプロピレングリコール、イソプレングリコール、ポリエチレングリコール、グリセリン、ポリグリセリン、ジグリセリン、及びソルビトールから選ばれる１種以上が挙げられる。これらの中でグリセリン、及びソルビトールから選ばれる１種以上が好ましく、多価アルコール類の配合量は特に限定されないが、難水溶性ビタミン、油成分、及び生薬抽出物から選ばれる１種以上の１質量部に対して通常は０．０２〜５００質量部、好ましくは０．０５〜２００質量部、より好ましくは１〜１００質量部である。 Examples of the polyhydric alcohol used in the present invention include one selected from ethylene glycol, propylene glycol, 1,3-butylene glycol, dipropylene glycol, isoprene glycol, polyethylene glycol, glycerin, polyglycerin, diglycerin, and sorbitol. The above is mentioned. Among these, at least one selected from glycerin and sorbitol is preferable, and the blending amount of polyhydric alcohols is not particularly limited, but at least one selected from poorly water-soluble vitamins, oil components, and herbal extracts. It is 0.02-500 mass parts normally with respect to a mass part, Preferably it is 0.05-200 mass parts, More preferably, it is 1-100 mass parts.
本発明の内服液体組成物は長期間保管後も透明な状態であり、更には長期間保管後の低温環境下でも沈殿物が生じずに透明な状態が維持された。ここで、低温とは好ましくは１０℃以下を意味し、さらに好ましくは５℃以下である。 The liquid composition for internal use of the present invention was in a transparent state even after long-term storage, and further maintained in a transparent state with no precipitation even in a low-temperature environment after long-term storage. Here, the low temperature preferably means 10 ° C. or less, more preferably 5 ° C. or less.
本発明の内服液体組成物のｐＨは、風味の点及び防腐性の点から２．０〜４．０が好ましい。ｐＨの調整には、例えば、クエン酸、リンゴ酸、フマル酸、酒石酸、乳酸及びコハク酸などの有機酸、又はこれら有機酸の塩、リン酸、塩酸などの無機酸、水酸化ナトリウムなどの無機塩基を用いることができる。本発明の内服液体組成物は、医薬品及び医薬部外品の他、栄養機能性食品、特定保険用食品等の食品領域における内服液剤として利用できる。 The pH of the internal liquid composition of the present invention is preferably 2.0 to 4.0 from the viewpoint of flavor and antiseptic properties. For adjusting the pH, for example, organic acids such as citric acid, malic acid, fumaric acid, tartaric acid, lactic acid and succinic acid, or salts of these organic acids, inorganic acids such as phosphoric acid and hydrochloric acid, inorganic acids such as sodium hydroxide, etc. A base can be used. The liquid composition for internal use of the present invention can be used as a liquid preparation for internal use in food fields such as nutritional functional foods and foods for specified insurance, in addition to pharmaceuticals and quasi drugs.
本発明の内服液体組成物には、水溶性ビタミン類、ミネラル類、アミノ酸類、ローヤルゼリー、カフェインなどを本発明の効果を損なわない範囲で適宜に配合できる。また、必要に応じて抗酸化剤、着色剤、香料、矯味剤、界面活性剤、溶解補助剤、保存剤、甘味料などの添加物を本発明の効果を損なわない範囲で適宜に配合することもできる。 In the internal liquid composition of the present invention, water-soluble vitamins, minerals, amino acids, royal jelly, caffeine and the like can be appropriately blended within a range not impairing the effects of the present invention. In addition, additives such as antioxidants, colorants, fragrances, flavoring agents, surfactants, solubilizers, preservatives, sweeteners, and the like are appropriately blended as necessary so long as the effects of the present invention are not impaired. You can also.
本発明の内服液体組成物を製造する方法は特に限定されるものではない。通常、ポリオキシエチレンラウリルエーテル、ポリオキシエチレンフィトステロール、又はポリオキシエチレンフィトスタノールと難水溶性ビタミン、油成分、又は生薬抽出物、及び多価アルコール類の各成分を適量の精製水に溶解した後、ｐＨを調整し、更に精製水を加えて容量調整し、必要に応じて濾過、滅菌処理を施すことにより、製造することができる。 The method for producing the internal liquid composition of the present invention is not particularly limited. Usually, after dissolving each component of polyoxyethylene lauryl ether, polyoxyethylene phytosterol, or polyoxyethylene phytostanol and sparingly water-soluble vitamins, oil components or herbal extracts, and polyhydric alcohols in appropriate amounts of purified water It can be produced by adjusting the pH, adjusting the volume by adding purified water, and performing filtration and sterilization treatment as necessary.
以下に、実施例、比較例、及び試験例を挙げ、本発明をより詳細に説明する．
実施例１〜４
表１に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンラウリルエーテル、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例１〜４とした。
Hereinafter, the present invention will be described in more detail with reference to examples, comparative examples, and test examples.
Examples 1-4
An internal liquid composition having the formulation shown in Table 1 was produced. First, polyoxyethylene lauryl ether, tocopherol acetate and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, citric acid was blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle, and a cap was applied to make Examples 1 to 4.
実施例５〜１０
表２に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンフィトステロール、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例５〜１０とした。
Examples 5-10
An internal liquid composition having the formulation shown in Table 2 was produced. First, polyoxyethylene phytosterol, tocopherol acetate, and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, citric acid was blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle, and a cap was applied to give Examples 5 to 10.
実施例１１〜１８
表３に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンフィトスタノール、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例１１〜１８とした。
Examples 11-18
An internal liquid composition having the formulation shown in Table 3 was produced. First, polyoxyethylene phytostanol, tocopherol acetate and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, citric acid was blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled into a glass bottle, and a cap was applied thereto, thereby providing Examples 11 to 18.
実施例１９〜２２
表４に示す処方の内服液体組成物を製造した。まず、ａ）ポリオキシエチレンラウリルエーテル、ｂ）ビタミンＤ、ビタミンＫ、酢酸トコフェロール、γ−オリザノールのうち１種または２種、ｃ）グリセリンまたはソルビトールを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液により ｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例１９〜２２とした。
Examples 19-22
An internal liquid composition having the formulation shown in Table 4 was produced. First, a) polyoxyethylene lauryl ether, b) one or two of vitamin D, vitamin K, tocopherol acetate, and γ-oryzanol, and c) glycerin or sorbitol are heated and mixed at 90 ° C. Dissolved with water. Next, citric acid was added, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled into a glass bottle, and a cap was applied thereto, and Examples 19 to 22 were obtained.
実施例２３〜２６
表５に示す処方の内服液体組成物を製造した。まず、ａ） ポリオキシエチレンフィトステロール、ｂ）ビタミンＤ、ビタミンＫ、酢酸トコフェロール、γ−オリザノールのうち１種または２種、ｃ）グリセリンまたはソルビトールを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例２３〜２６とした。
Examples 23-26
An internal liquid composition having the formulation shown in Table 5 was produced. First, a) polyoxyethylene phytosterol, b) one or two of vitamin D, vitamin K, tocopherol acetate and γ-oryzanol, and c) glycerin or sorbitol are heated and mixed at 90 ° C. Was dissolved. Next, citric acid was blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle and capped, and Examples 23 to 26 were obtained.
実施例２７〜３１
表６に示す処方の内服液体組成物を製造した。まず、ａ） ポリオキシエチレンフィトスタノール、ｂ）ビタミンＤ、ビタミンＫ、酢酸トコフェロール、γ−オリザノールのうち１種または２種、ｃ）グリセリンまたはソルビトールを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例２７〜３１とした。
Examples 27-31
An internal liquid composition having the formulation shown in Table 6 was produced. First, a) polyoxyethylene phytostanol, b) one or two of vitamin D, vitamin K, tocopherol acetate and γ-oryzanol, and c) glycerin or sorbitol are heated and mixed at 90 ° C. Dissolved with water. Next, citric acid was blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle and capped, and Examples 27 to 31 were obtained.
実施例３２〜３４
表７に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンラウリルエーテル、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した、次にニンジンエキス、カンゾウエキス、チンピエキスのいずれか１種とクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例３２〜３４とした。
Examples 32-34
An internal liquid composition having the formulation shown in Table 7 was produced. First, polyoxyethylene lauryl ether, tocopherol acetate, and glycerin were heated and mixed at 90 ° C., and then dissolved in water at room temperature. Next, any one of carrot extract, liquorice extract, and chimpi extract was mixed with citric acid. The pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle, and a cap was applied to give Examples 32-34.
実施例３５〜３７
表８に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンフィトステロール、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にニンジンエキス、カンゾウエキス、チンピエキスのいずれか１種とクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例３５〜３７とした。
Examples 35-37
An internal liquid composition having the formulation shown in Table 8 was produced. First, polyoxyethylene phytosterol, tocopherol acetate, and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, any one of a carrot extract, a licorice extract and a chimney extract and citric acid were blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle and capped, and Examples 35 to 37 were obtained.
実施例３８〜４０
表９に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンフィトスタノール、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にニンジンエキス、カンゾウエキス、チンピエキスのいずれか１種とクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例３８〜４０とした。
Examples 38-40
An internal liquid composition having the formulation shown in Table 9 was produced. First, polyoxyethylene phytostanol, tocopherol acetate and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, any one of a carrot extract, a licorice extract and a chimney extract and citric acid were blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle, and a cap was applied to give Examples 38 to 40.
実施例４１、４２
表１０に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンラウリルエーテル、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液または１ｍｏｌ／Ｌの塩酸によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例４１、４２とした。
Examples 41 and 42
An internal liquid composition having the formulation shown in Table 10 was produced. First, polyoxyethylene lauryl ether, tocopherol acetate and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, citric acid was added, and the pH was adjusted with a 4 mol / L aqueous sodium hydroxide solution or 1 mol / L hydrochloric acid. These were filled into glass bottles and capped, and Examples 41 and 42 were obtained.
実施例４３、４４
表１１に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンフィトステロール、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液または１ｍｏｌ／Ｌの塩酸によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例４３、４４とした。
Examples 43 and 44
An internal liquid composition having the formulation shown in Table 11 was produced. First, polyoxyethylene phytosterol, tocopherol acetate, and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, citric acid was added, and the pH was adjusted with a 4 mol / L aqueous sodium hydroxide solution or 1 mol / L hydrochloric acid. These were filled in a glass bottle and capped, and Examples 43 and 44 were obtained.
実施例４５、４６
表１２に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンフィトスタノール、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液または１ｍｏｌ／Ｌの塩酸によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、実施例４５、４６とした。
Examples 45 and 46
An internal liquid composition having the formulation shown in Table 12 was produced. First, polyoxyethylene phytostanol, tocopherol acetate and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, citric acid was added, and the pH was adjusted with a 4 mol / L aqueous sodium hydroxide solution or 1 mol / L hydrochloric acid. These were filled in a glass bottle and capped, and Examples 45 and 46 were obtained.
比較例１及び比較例２
表１３に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレン硬化ヒマシ油、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、比較例１〜２とした。
Comparative Example 1 and Comparative Example 2
An internal liquid composition having the formulation shown in Table 13 was produced. First, polyoxyethylene hydrogenated castor oil, tocopherol acetate, and glycerin were heated and mixed at 90 ° C., and then dissolved in water at room temperature. Next, citric acid was blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle, and a cap was applied to make Comparative Examples 1 and 2.
比較例３及び比較例４
表１３に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンセチルエーテル（ＰＯＥ（３０））、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、比較例３〜４とした。
Comparative Example 3 and Comparative Example 4
An internal liquid composition having the formulation shown in Table 13 was produced. First, polyoxyethylene cetyl ether (POE (30)), tocopherol acetate and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, citric acid was blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle, and a cap was applied to make Comparative Examples 3 to 4.
比較例５及び比較例６
表１３に示す処方の内服液体組成物を製造した。まず、ポリオキシエチレンセチルエーテル（ＰＯＥ（４０））、酢酸トコフェロール、グリセリンを９０℃にて加温混合した後、常温の水により溶解した。次にクエン酸を配合し、４ｍｏｌ／Ｌの水酸化ナトリウム水溶液によりｐＨを調整した。これらをガラス瓶に充填し、キャップを施し、比較例５〜６とした。
Comparative Example 5 and Comparative Example 6
An internal liquid composition having the formulation shown in Table 13 was produced. First, polyoxyethylene cetyl ether (POE (40)), tocopherol acetate and glycerin were heated and mixed at 90 ° C. and then dissolved in water at room temperature. Next, citric acid was blended, and the pH was adjusted with a 4 mol / L sodium hydroxide aqueous solution. These were filled in a glass bottle, and a cap was applied to make Comparative Examples 5 to 6.
試験例
実施例１〜４６、及び比較例１〜６を６５℃の恒温槽中で４週間保存後、５℃で１日冷却し（表中では６５℃−４Ｗ＋５℃−１Ｄと略記する）、内服液体組成物中の沈殿及び浮遊物を目視により観察した。結果を表１〜１３に示す。なお、沈殿及び浮遊物の程度は以下の基準により判定した。
Test Examples Examples 1 to 46 and Comparative Examples 1 to 6 were stored in a constant temperature bath at 65 ° C for 4 weeks and then cooled at 5 ° C for 1 day (in the table, abbreviated as 65 ° C-4W + 5 ° C-1D). The precipitates and suspended solids in the internal liquid composition were visually observed. The results are shown in Tables 1-13. The degree of precipitation and suspended matter was determined according to the following criteria.
性状の観察基準
不溶物なし ： −
不溶物少量あり ： ＋
不溶物多量にあり：＋＋
Observation criteria for properties No insoluble matter: −
There is a small amount of insoluble matter: +
There is a large amount of insoluble matter: ++
以上の結果より、ポリオキシエチレンラウリルエーテル、ポリオキシエチレンフィトステロール、及びポリオキシエチレンフィトスタノールから選ばれる１種以上を配合することで、難水溶性ビタミンを長期間安定に溶解させることができ、かつ長期間保管しても濁りや沈殿を生成しないことを確認した。 From the above results, by blending one or more selected from polyoxyethylene lauryl ether, polyoxyethylene phytosterol, and polyoxyethylene phytostanol, the poorly water-soluble vitamin can be stably dissolved for a long time, and It was confirmed that no turbidity or precipitation was generated even after long-term storage.
本発明により、医薬品、医薬部外品、又は食品の分野において難水溶性ビタミン、油成分、又は生薬抽出物を含有する内服液剤として提供することが期待される。 According to the present invention, it is expected to be provided as an internal solution containing a poorly water-soluble vitamin, an oil component, or a herbal extract in the field of pharmaceuticals, quasi drugs, or foods.
Claims (8)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012213960 | 2012-09-27 | ||
| JP2012213960 | 2012-09-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538511A Division JP6260538B2 (en) | 2012-09-27 | 2013-09-25 | Oral liquid composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018039827A true JP2018039827A (en) | 2018-03-15 |
| JP6418305B2 JP6418305B2 (en) | 2018-11-07 |
Family
ID=50388248
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538511A Active JP6260538B2 (en) | 2012-09-27 | 2013-09-25 | Oral liquid composition |
| JP2017202409A Active JP6418305B2 (en) | 2012-09-27 | 2017-10-19 | Oral liquid composition |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538511A Active JP6260538B2 (en) | 2012-09-27 | 2013-09-25 | Oral liquid composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (2) | JP6260538B2 (en) |
| TW (1) | TW201427715A (en) |
| WO (1) | WO2014050851A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6132947B1 (en) * | 2016-03-24 | 2017-05-24 | アサヒ飲料株式会社 | Method for adjusting the stability of beverages and lutein in beverages |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS615011A (en) * | 1984-06-18 | 1986-01-10 | Ss Pharmaceut Co Ltd | Stable vitamin e solubilized solution |
| JPH083074A (en) * | 1994-06-21 | 1996-01-09 | Sunstar Inc | Liquid composition for mouth |
| JP2002128703A (en) * | 2000-10-25 | 2002-05-09 | Taisho Pharmaceut Co Ltd | Crude drug blended solubilized liquid composition |
| JP2002128672A (en) * | 2000-10-25 | 2002-05-09 | Taisho Pharmaceut Co Ltd | Solubilized liquid composition |
| JP2003503440A (en) * | 1999-06-30 | 2003-01-28 | リポシン インコーポレイテッド | Pharmaceutical composition containing clear oil |
| JP2003201231A (en) * | 2001-12-28 | 2003-07-18 | Lion Corp | Emulsion composition |
| JP2003206242A (en) * | 2001-12-28 | 2003-07-22 | Lion Corp | Internal liquid medicine composition |
| JP2004173641A (en) * | 2002-11-29 | 2004-06-24 | Ogawa & Co Ltd | Spraying syrup composition |
| JP2004173640A (en) * | 2002-11-29 | 2004-06-24 | Ogawa & Co Ltd | Spraying syrup composition |
| JP2009013234A (en) * | 2007-07-02 | 2009-01-22 | Fujifilm Corp | Powdery composition, method for producing the same, and foodstuff composition, cosmetics composition and medicinal composition containing the same |
| JP2009051810A (en) * | 2007-07-27 | 2009-03-12 | Shiseido Co Ltd | Oil-in-water type emulsified composition and method for producing the same |
| JP2009292771A (en) * | 2008-06-05 | 2009-12-17 | Kowa Co | Orally applicable pharmaceutical composition containing hydrophilic surfactant |
| JP2010053150A (en) * | 2003-02-19 | 2010-03-11 | Kose Corp | Oil-in-water type emulsified cosmetic |
| JP2013112650A (en) * | 2011-11-29 | 2013-06-10 | Kao Corp | Liquid composition for oral cavity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4863589B2 (en) * | 2001-09-28 | 2012-01-25 | ロート製薬株式会社 | Aqueous composition |
| JP2006219409A (en) * | 2005-02-09 | 2006-08-24 | Rohto Pharmaceut Co Ltd | Pranoprofen-containing aqueous composition |
| JP2008031165A (en) * | 2006-07-05 | 2008-02-14 | Rohto Pharmaceut Co Ltd | Aqueous composition containing vitamin a compound |
| JP4657323B2 (en) * | 2008-07-02 | 2011-03-23 | 株式会社資生堂 | Water-containing composition |
| JP2011236144A (en) * | 2010-05-10 | 2011-11-24 | Lion Corp | Composition for oral cavity, and foul-breath inhibitor |
-
2013
- 2013-09-25 JP JP2014538511A patent/JP6260538B2/en active Active
- 2013-09-25 WO PCT/JP2013/075823 patent/WO2014050851A1/en active Application Filing
- 2013-09-26 TW TW102134785A patent/TW201427715A/en unknown
-
2017
- 2017-10-19 JP JP2017202409A patent/JP6418305B2/en active Active
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS615011A (en) * | 1984-06-18 | 1986-01-10 | Ss Pharmaceut Co Ltd | Stable vitamin e solubilized solution |
| JPH083074A (en) * | 1994-06-21 | 1996-01-09 | Sunstar Inc | Liquid composition for mouth |
| JP2003503440A (en) * | 1999-06-30 | 2003-01-28 | リポシン インコーポレイテッド | Pharmaceutical composition containing clear oil |
| JP2002128703A (en) * | 2000-10-25 | 2002-05-09 | Taisho Pharmaceut Co Ltd | Crude drug blended solubilized liquid composition |
| JP2002128672A (en) * | 2000-10-25 | 2002-05-09 | Taisho Pharmaceut Co Ltd | Solubilized liquid composition |
| JP2003206242A (en) * | 2001-12-28 | 2003-07-22 | Lion Corp | Internal liquid medicine composition |
| JP2003201231A (en) * | 2001-12-28 | 2003-07-18 | Lion Corp | Emulsion composition |
| JP2004173641A (en) * | 2002-11-29 | 2004-06-24 | Ogawa & Co Ltd | Spraying syrup composition |
| JP2004173640A (en) * | 2002-11-29 | 2004-06-24 | Ogawa & Co Ltd | Spraying syrup composition |
| JP2010053150A (en) * | 2003-02-19 | 2010-03-11 | Kose Corp | Oil-in-water type emulsified cosmetic |
| JP2009013234A (en) * | 2007-07-02 | 2009-01-22 | Fujifilm Corp | Powdery composition, method for producing the same, and foodstuff composition, cosmetics composition and medicinal composition containing the same |
| JP2009051810A (en) * | 2007-07-27 | 2009-03-12 | Shiseido Co Ltd | Oil-in-water type emulsified composition and method for producing the same |
| JP2009292771A (en) * | 2008-06-05 | 2009-12-17 | Kowa Co | Orally applicable pharmaceutical composition containing hydrophilic surfactant |
| JP2013112650A (en) * | 2011-11-29 | 2013-06-10 | Kao Corp | Liquid composition for oral cavity |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2014050851A1 (en) | 2016-08-22 |
| TW201427715A (en) | 2014-07-16 |
| WO2014050851A1 (en) | 2014-04-03 |
| JP6418305B2 (en) | 2018-11-07 |
| JP6260538B2 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6060742B2 (en) | Liquid composition for external use | |
| TWI667040B (en) | Method for producing liquid oral composition and liquid oral composition | |
| JP6418305B2 (en) | Oral liquid composition | |
| CN104352566A (en) | Oil-in-water compound chlortetracycline nanoemulsion | |
| JP2006257010A (en) | WATER-SOLUBLE COMPOSITION OF alpha-LIPOIC ACID, BEVERAGE OR FOOD AND COSMETIC EACH CONTAINING THE SAME COMPOSITION AND METHOD FOR PRODUCING THE SAME COMPOSITION | |
| WO2005034913A1 (en) | Novel liquid preparation composition | |
| JP6519248B2 (en) | Crude drug extract-containing beverage | |
| ES2795104T3 (en) | Plant phenols and their use in the treatment or prevention of eosinophilic esophagitis | |
| JP6869129B2 (en) | Aqueous gel composition for whitening | |
| JP2009225790A (en) | Beverage | |
| JP2002128703A (en) | Crude drug blended solubilized liquid composition | |
| JP2008120748A (en) | gamma-ORYZANOL-SOLUBILIZED LIQUID COMPOSITION | |
| JP5643912B1 (en) | Propolis extract and method for producing the same, capsule, and antioxidant | |
| JP2018002639A (en) | Acidic composition containing folic acid with excellent stability | |
| JP6024371B2 (en) | Herbal extract-containing liquid composition | |
| TW201622712A (en) | Pharmaceutical composition for external use | |
| JP2002193825A (en) | Liquid composition | |
| JP6084579B2 (en) | Oil-in-water cream composition containing tacrolimus | |
| JP2015105243A (en) | Ubiquinol-containing liquid composition | |
| JP2020002059A (en) | External composition | |
| JP5682118B2 (en) | Folic acid-containing beverage | |
| JP6177638B2 (en) | Skin external preparation for whitening | |
| JP4697123B2 (en) | Royal jelly-containing beverage composition | |
| JP5953660B2 (en) | Royal jelly-containing liquid composition | |
| JP5849384B2 (en) | Folic acid-containing beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180911 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180924 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6418305 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |